CureApp, Inc. implemented a third party allotment of new shares totaling 380 million JPY
CureApp, Inc. (headquartered in Chuo-ku, Tokyo: President and CEO: Kota Satake) which is engaged in the research and development of therapeutic applications as medical devices as well as their manufacture and sale, has today announced that Beyond Next Ventures and Keio Innovation has implemented a third party allotment capital of 380 million JYN taken on by SBI Investments. [Overview of Underwrite] Beyond Next Ventures Head Office: 1-4-3 Nihonbashi Honcho, Chuo-ku, Tokyo Representative Director and President: Takeshi Ito Keio Innovation Initiative Headquarters: Mita 1-4-28, Minato-ku, Tokyo Representative Director: Hirotaro Yamagishi SBI Investment Head office: 1-6-1 Roppongi, Minato-ku, Tokyo Representative Director and Executive Officer President: Katsuya Kawashima [Implementation Background and Objectives] CureApp aims to create individually optimized (personalized) medical care that achieves a superb therapeutic effect as a form of new medical treatment